China Resources Medical's backdoor Phoenix medical curve listed medical resources integration can really achieve "healing" and "complementary"?

The medical resources in China's medical market are chaotic and the management is lacking. How can we see the entry and exit of social capital in the "red medical resources" world?

As for some of the focus issues, our reporter has visited the “Special Forces” who are the legal and risk control person in charge of a foreign-funded medical investment group, and personally led the senior partnership of Beijing Dongyuan Crane Law Firm, which has acquired many medical institutions. Mr. Bao Yanfeng, a master of economics and economic law, commented on the Huarun Medical's backdoor Phoenix medical incident. The following is an excerpt from the talks.

What is your first reaction to “China Resources Medical's Backdoor Phoenix Medical Curve”?

A: I am not surprised that this China Resources has been added to the main Phoenix Medical. China Resources Medical has this strength to enter the capital market and has the strength to win Phoenix Medical. It is such a huge transaction, and it is hard to do DD colleagues, the law, The financial, evaluation, medical bills of the brigade and the secondary market of the Stock Exchange have been coordinated. The transaction has been in operation for at least 2 years. It is basically consistent with the time of Fu Yuning’s appointment. The market outlook is a lot...

What do you think of the “what is the point” in the merger?

A: Actually, from the experience of medical investment in “fusing, investing, managing, and retreating” in my years, I personally admire the joint efforts of China Resources Medical and Phoenix Medical. Why do you say this? "Financing" is not mentioned, the two current status of the rivers and lakes as long as the investment target is basically not lost, I refer to the perspective of the pool of funds, the general medical investment institutions meet the good investment targets many times "Scared in the bag." When it comes to "investment", the medical resources of China Resources Medical are all "passive" into the territory. Many resources are resource adjustments within the family members of the "big family" of China Resources Group. It is not a completely market-oriented behavior. The acquisition of Huaibei Mining Hospital is the result of the “parental life” caused by the “debt handling” of China Resources Gas and the local government and Huaibei Mining Bureau, rather than “love at first sight”. Phoenix Medical is different. As a leader of China's private medical institutions, it is deeply rooted in the Beijing medical market and has a basic monopoly on the Mentougou medical market. Phoenix Medical can always find and win the medical assets of “Jadei”, such as the Beijing Coal General Hospital. Such a low valuation and the establishment of the General Administration of Safety Supervision and the introduction of CITIC Trust, the executive power did not have to say, of course, not so cheap Things, it seems that the media reported that Phoenix encountered the conflict of employees, and the follow-up did not pay attention to it... The two companies joined forces, with the "quasi-star" of Phoenix Medical, and the "bullet" of China Resources Medical, the follow-up should have a lot of prey. Let me talk about the issue of "management". There are too many things to watch and time is limited. I will simply pick a few points. The medical institutions of China Resources Medical are basically medical institutions within the system. Simple personnel appointment and dismissal is fine. There will be no What is wrong and shock, because China Resources represents the country. Phoenix Medical is different. With the investment of funds and the establishment of “BOT” mode, the business model is very fragile. Only by careful and cautious “care” can guarantee the security of its business model. At the same time, its own business model also has problems. . In practice, profits are “managed”. Can Phoenix Medical’s excellent management system be effectively and comprehensively infiltrated into China Resources Medical’s asset group? At the same time, can Huaneng Medical's supply chain segment, Phoenix Medical, be able to “get into the finger”? Very imaginative space. Finally, to say "retreat" is nothing more than making assets into listed companies in the medical sector or listed companies in transition, or listing on their own, but in terms of the current IPO conditions of the capital market, "long roads", capital, etc. Can't afford, or sell to pension funds, people must have a stable fixed return, and these are the main types. At present, the Internet concept of the medical sector is very hot, and the professional services of various professional vertical subdivisions are constantly maturing and scattered. The attention of medical capital, but the hospital as the terminal of consumption and the largest "physical store", "O2O" "offline", its value and status is unquestionable, the military is the place to fight!

N Isopropylbenzylamine

ynephrine (or oxedrine) is a drug commonly used for weight loss. While its effectiveness is widely debated, synephrine has gained si

ynephrine (or oxedrine) is a drug commonly used for weight loss. While its effectiveness is widely debated, synephrine has gained significant popularity as an alternative to, a related substance which has been made illegal or restricted in many countries due to health risks and its use as a precursor in the illicit manufacturing.

There is however no occurrence of diverted synephrine for the manufacture of amphetamines, and the naturally occurring synephrine is, due to its phenolic group, unsuitable for such diversion.

Products containing bitter orange or synephrine are suspected of causing adverse cardiovascular reactions. Synephrine is derived primarily from the immature fruit of Citrus aurantium, a relatively small citrus tree, of which several of its more common names include Bitter Orange, Sour Orange, and Zhi shi. Dietary supplements generally supply single oral doses of 3–30 mg, while as a pharmaceutical agent it is given orally or by parenteral injection in 20–100 mg doses as a vasoconstrictor to hypotensive patients.

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Describe :

item	Synephrine hydrochloride
CAS No.	5985-28-4
Other Names	N-Isopropylnorsynephrine HCL
MF	C9H14ClNO2
EINECS No.	/
Place of Origin	China
Type	Pharmaceutical Intermediates, Syntheses Material Intermediates
Purity	99%
Brand Name	Vanz
Model Number	Vanz20210420
Application	sport nutrition
Appearance	white powder
Product Name	Synephrine hydrochloride
CAS	5985-28-4
Appearance	white powder
Shelf life	2 Years
Package	25kg/drum
Certificate	ISO9001
Storage	Cool Dried Storage
Test Method	HPLC Test
Payment term	TT.Western Union .Credit Card
Assay	99%min

product name:

gnificant popularity as an alternative to, a related substance which has been made illegal or restricted in many countries due to health risks and its use as a precursor in the illicit manufacturing.

There is however no occurrence of diverted synephrine for the manufacture of amphetamines, and the naturally occurring synephrine is, due to its phenolic group, unsuitable for such diversion.

Products containing bitter orange or synephrine are suspected of causing adverse cardiovascular reactions. Synephrine is derived primarily from the immature fruit of Citrus aurantium, a relatively small citrus tree, of which several of its more common names include Bitter Orange, Sour Orange, and Zhi shi. Dietary supplements generally supply single oral doses of 3–30 mg, while as a pharmaceutical agent it is given orally or by parenteral injection in 20–100 mg doses as a vasoconstrictor to hypotensive patients.

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Describe :

N Isopropylbenzylamine,Inositol Powder,Best Inositol Powder,Benzylisopropylamine Cas 102-97-6

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropic.com